| Literature DB >> 31561559 |
Seung Don Baek1, Soomin Jeung2, Jae-Young Kang3.
Abstract
BACKGROUND: Latent tuberculosis infection (LTBI) is prevalent in end-stage renal disease (ESRD) patients. The risk of tuberculosis activation is also high. The appropriate LTBI screening and treatment is required in this population. Meanwhile, whether hemodialysis adequacy is associated with LTBI in the ESRD population is unclear. In this study, we aimed to investigate the association between hemodialysis adequacy and LTBI in ESRD patients.Entities:
Keywords: dialysis; kidney failure; latent tuberculosis
Mesh:
Substances:
Year: 2019 PMID: 31561559 PMCID: PMC6835669 DOI: 10.3390/nu11102299
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Baseline characteristics of the groups according to interferon gamma release assay.
| Negative IGRA ( | Positive IGRA ( | ||
|---|---|---|---|
| Age (years) | 61.3 ± 13.5 | 62.8 ± 9.1 | 0.656 |
| Male | 44 (62.9%) | 12 (60.0%) | 1.000 |
| Body mass index (kg/m2) | 23.0 ± 3.1 | 23.5 ± 3.5 | 0.525 |
| Dialysis type (hemodialysis vs. peritoneal dialysis) | 64 (91.4%) vs. 6 (8.6%) | 20 (100.0%) vs. 0 (0%) | 0.397 |
| Dialysis vintage (months) | 18.0 (10.0–53.0) | 23.0 (15.0–60.0) | 0.302 |
| Comorbidity | |||
| Diabetes | 33 (47.8%) | 13 (65.0%) | 0.272 |
| Hypertension | 65 (94.2%) | 20 (100.0%) | 0.625 |
| Chronic glomerulonephritis | 13 (18.8%) | 1 (5.0%) | 0.251 |
| Coronary artery disease | 28 (40.6%) | 6 (30.0%) | 0.551 |
| Cerebrovascular disease | 3 (4.3%) | 3 (15.0%) | 0.243 |
| Prior tuberculosis treatment | 1 (1.4%) | 1 (5.0%) | 0.931 |
| Old fibrotic changes on chest radiograph | 7 (10.1%) | 11 (55.0%) | <0.005 |
| Immunosuppressant medication | 3 (4.3%) | 0 (0.0%) | 0.806 |
| Systolic blood pressure (mmHg) | 144.8 ± 20.1 | 147.0 ± 22.4 | 0.679 |
| Diastolic blood pressure (mmHg) | 69.7 ± 14.9 | 66.0 ± 14.7 | 0.334 |
| Heart rate (rate/min) | 69.5 (63.0–77.0) | 72.5 (68.5–78.5) | 0.158 |
| Interdialytic weight gain (hemodialysis patients only) | 2.4 ± 1.0 | 2.4 ± 1.1 | 0.919 |
| Hemoglobin, g/dL | 10.1 (9.5–10.8) | 10.2 (9.6–10.6) | 0.829 |
| Albumin, g/dL | 3.8 (3.5–4.0) | 3.8 (3.4–3.9) | 0.429 |
| Ferritin, ug/L | 201.0 (98.2–309.9) | 204.6 (115.4–296.4) | 0.884 |
| Transferrin saturation, % | 26.7 (21.3–36.0) | 32.3 (25.3–38.5) | 0.367 |
| Calcium, mg/dL | 8.9 ± 0.7 | 8.9 ± 0.7 | 0.957 |
| Phosphorus, mg/dL | 4.4 (3.7–5.5) | 4.4 (3.8–5.2) | 0.775 |
| Intact parathyroid hormone, pg/mL | 140.0 (87.7–238.0) | 194.0 (85.3–321.0) | 0.338 |
| Single-pool Kt/V | 1.5 ± 0.3 | 1.5 ± 0.2 | 0.590 |
| Normalized protein catabolic rate, g/kg/day | 1.0 ± 0.2 | 0.8 ± 0.1 | <0.005 |
IGRA, interferon gamma release assay.
Figure 1Box plot comparison of normalized protein catabolic rate (A) and Kt/V (B) between the two groups.
Variables associated with latent tuberculosis infection.
| Variables | Adjusted Hazard Ratio (95% Confidence Interval) | |
|---|---|---|
| Old fibrotic changes | 11.93 (3.17–44.85) | <0.005 |
| nPCR less than 0.87 g/kg/day | 7.74 (1.77–33.74) | 0.006 |
nPCR, normalized protein catabolic rate.
Baseline characteristics of the groups according to normalized protein catabolic rate.
| Normalized Protein Catabolic Rate (g/kg/day) | >0.87 ( | ≤0.87 ( | |
|---|---|---|---|
| Age (years) | 58.5 ± 12.0 | 64.2 ± 12.6 | 0.031 |
| Male | 24 (58.5%) | 32 (65.3%) | 0.659 |
| Body mass index (kg/m2) | 22.8 ± 3.1 | 23.3 ± 3.3 | 0.445 |
| Dialysis type (hemodialysis vs. peritoneal dialysis) | 41 (100.0%) vs. 0 (0.0%) | 43 (87.8%) vs. 6 (12.2%) | 0.058 |
| Dialysis vintage (months) | 23.0 (12.0–60.0) | 20.0 (9.0–44.5) | 0.358 |
| Comorbidity | |||
| Diabetes | 19 (46.3%) | 27 (56.2%) | 0.472 |
| Hypertension | 37 (90.2%) | 48 (100.0%) | 0.089 |
| Chronic glomerulonephritis | 9 (22.0%) | 5 (10.4%) | 0.231 |
| Coronary artery disease | 12 (29.3%) | 22 (45.8%) | 0.166 |
| Cerebrovascular disease | 1 (2.4%) | 5 (10.4%) | 0.284 |
| Prior tuberculosis treatment | 0 (0.0%) | 2 (4.2%) | 0.545 |
| Old fibrotic changes on chest radiograph | 6 (14.6%) | 12 (25.0%) | 0.343 |
| Immunosuppressant medication | 2 (4.9%) | 1 (2.1%) | 0.889 |
| Pre-dialysis systolic blood pressure (mmHg) | 148.8 ± 22.7 | 142.4 ± 18.3 | 0.141 |
| Pre-dialysis diastolic blood pressure (mmHg) | 71.4 ± 12.1 | 66.7 ± 16.6 | 0.127 |
| Pre-dialysis heart rate (rate/min) | 69.0 (64.0–75.0) | 72.0 (64.0–80.0) | 0.200 |
| Interdialytic weight gain (hemodialysis patients only) | 2.4 ± 1.0 | 2.4 ± 1.1 | 0.901 |
| Hemoglobin, g/dL | 10.3 (9.9–0.8) | 9.9 (9.3–10.5) | 0.038 |
| Albumin, g/dL | 3.9 (3.7–4.0) | 3.7 (3.4–3.9) | 0.003 |
| Ferritin, ug/L | 179.8 (95.0–308.5) | 221.5 (134.7–309.9) | 0.509 |
| Transferrin saturation, % | 28.6 (21.1–39.1) | 28.0 (23.2–36.0) | 0.946 |
| Calcium, mg/dL | 9.1 ± 0.6 | 8.7 ± 0.7 | 0.010 |
| Phosphorus, mg/dL | 4.5 (3.8–5.5) | 4.3 (3.7–5.3) | 0.760 |
| Intact parathyroid hormone, pg/mL | 153.0 (97.0–239.0) | 141.0 (71.1–243.0) | 0.840 |
| Single-pool Kt/V | 1.6 ± 0.2 | 1.4 ± 0.2 | 0.026 |